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Introduction
Recent studies have shown that bone marrow 
mononuclear cell (BM-MNC) therapy improves 
exercise capacity in patients with more advanced 
chronic heart failure (HF) [1]. However, few stud-
ies have explored the safety profile and efficacy 
of allogeneic umbilical cord blood mononuclear 
cells (CB-MNCs) administered intravenously to 
patients with CHF. 
The umbilical cord blood was taken from 
healthy full-term and naturally delivered newborns 
after written informed consent were obtained from 
their mothers and other family members. The 
study protocol was reviewed and approved by the 
hospital review board and ethics committee of 
Taizhou People’s Hospital (Taizhou, China). Also, 
the study protocol was performed in compliance 
with current Good Clinical Practice standards.
Case presentation
A 68-year-old man was sent to a nearby com-
munity hospital because of chest pain and was di-
agnosed as myocardial infarction (MI) in September 
2008. The main symptoms of acute MI were as 
follows: (1) bosom frowsty chest pain; (2) dynamic 
changes of MI, as shown in electrocardiogram 
(ECG); (3) peak creatine kinase-MB level exceed-
ing 100 U/L (upper limit of normal < 24 U/L). 
According to conditions of hospital treatment, the 
patient was treated with thrombolytic therapy ac-
cording to ACC/AHA about ST-segment elevation 
MI treatment guidelines [2, 3]. After thrombolysis, 
the patient had ventricular fibrillation, HF and 
pulmonary infection. The patient was transferred 
to our hospital for coronary angiography and stent 
implantation (implantation site: anterior descend-
ing branch) in September 2008 and heart function 
was class III–IV according to ACC heart function 
classification standard. But after percutaneous 
coronary intervention treatment, patient continued 
to report chest tightness, shortness of breath, even 
when he slightly stretched himself. 
Drug therapy, coronary angiography and stent 
implantation were given. Drug therapy: enteric-
-coated aspirin 100 mg once per night, clopidogrel 
75 mg once each morning, atorvastatin once per 
night, angiotensin converting enzyme inhibitor 
once each morning, low molecular weight heparin 
morning and evening (12 h apart) subcutaneously. 
In addition to low molecular weight heparin for 
7 days, others were administered continuously. 
Every morning furosemide 20 mg and spironolac-
tone 20 mg were administered until the operation. 
Operation: Coronary angiography suggested that 
the middle left anterior descending artery (LAD) 
stenosis was nearly 99% and the first diagonal 
branch stenosis 70%. A Cypher (Cordis) was im-
plantated in the LAD. The patient showed severe 
HF. Nine months later, an alternative approach with 
CB-MNCs was applied to the patient.
The content of CD34+ was 0.28%, 0.32%, 
0.25%, and 0.26%. The cell viability of CB-MNCs 
was 98%, 96%, 99%, and 98%. Without cryopreser-
vation and thawing, 2.0 × 107 allogeneic CB-MNCs 
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Figure 1. Parameters tracking before and after treatment; A. The infarct region was determined by single-photon emis-
sion computed tomography after myocardial infarction (MI), 3 months and 1 year post-transplantation. Compared to 
before and after treatment the infarct size was considerably reduced by 11%; B. The left ventricular ejection fraction 
(LVEF) from 3 months after MI to 6 years after therapy; C. The serum level of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) reached a peak (14,130 pg/mL) about 9 months after the onset of symptoms. After cord blood mono-
nuclear cells (CB-MNC) therapy, the serum level of NT-proBNP was maintained at a lower level during the follow-up 
period; D. The patient’s activity improved significantly after CB-MNC therapy. After therapy plus exercise, the patient 
could walk more than 400 m in 6 min during the follow-up period; E. The diameters of left ventricle was continuously 
monitored since it could reflect the size of the heart; F. The left ventricle diastolic volumes reduced 1 month after 
treatment and rebounded slightly 3 years after treatment; M — months; Y — years.
were resuspended in 30 mL of 0.9% saline. Before 
infusion, 5 mg dexamethasone and 25 mg phenergan 
were added to prevent response every time. CB-
-MNCs were intravenously injected. The patient 
received four treatments once a week. All adverse 
events were monitored, particularly during cell 
administration. Twenty-four-hour ECG recordings 
were performed 24–48 h after cell administration.
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In-hospital patient monitoring  
and post-discharge follow-up
Three months after intravenous CB-MNC 
transplantation, the left ventricular ejection frac-
tion (LVEF) improved significantly by 20%. The 
initial improvement in the cardiac function was 
maintained even after 6 years (Fig. 1B). The in-
farct size considerably reduced by 11%, which was 
determined by single-photon emission computed 
tomography after MI and 3 months post-transplan-
tation. Compared to 3 months after treatment, the 
infarct size was not significantly changed 1 year 
post-transplantation (Fig. 1A). 
The serum level of N-terminal pro–B-type 
natriuretic peptide (NT-proBNP) reached a peak 
(14,130 pg/mL, reference range: < 75 years old, 
< 250 pg/mL) about 9 months after the onset of 
symptoms. A high level of NT-proBNP may reflect 
an acute phase reaction to the extent and sever-
ity of the initial ischemic insult. After treatment, 
the serum level of NT-proBNP was maintained at 
a lower level (< 900 pg/mL) (Fig. 1C).
The patient’s activity improved significantly 
after CB-MNC therapy. After treatment and ex-
ercise, the patient could walk more than 400 m in 
6 min during the follow-up period (Fig. 1D). The 
diameters of left ventricle and it’s volumes are 
shown in Figure 1E and 1F and the size of heart is 
an essential parameter for patients with HF.
Discussion
This study assessed LVEF using echocardiog-
raphy. The patient showed a significant increase in 
LVEF 3 months after therapy. The most fundamen-
tal objective was to reduce the infarct area, which 
caused HF. CB-MNCs therapy is likely to save the 
stunning myocardium before myocardial necrosis and 
fibrous connective tissue replacement. The patient 
with chest tightness, shortness of breath symptoms 
improved significantly and exercise tolerance had 
increased compared to previous levels. The outcomes 
were consistent with those reported earlier [4].
After CB-MNC therapy, the serum level of 
NT-proBNP showed a sharp decline and was 
maintained at a lower level. There may have been 
a minor placebo effect on the 6-min walk test. The 
result of the 6-min walk test and the serum level of 
NT-proBNP were negatively correlated 6 months 
after therapy. The heart function of the patient was 
basically maintained at class II–III 3 months after 
therapy according to Canadian Cardiovascular So-
ciety patient grading. Overall, an improvement in 
the left ventricular cardiac function and a reduction 
in the infarct size were induced by CB-MNCs in 
patients with chronic HF.
Conclusions
Left ventricular function improvement indi-
cated that allogeneic CB-MNC transplantation is 
safe and may be effective in patients with CHF. 
However, the role of allogeneic CB-MNCs in 
the treatment of chronic HF needs to be further 
investigated.
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